Real-World study tests Trimbow's impact on severe COPD symptoms
NCT ID NCT07406048
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is tracking about 400 adults with severe or very severe COPD in Brazil who are taking the triple-combination inhaler Trimbow. Researchers will measure changes in symptoms and lung function over 6 months during routine doctor visits. The goal is to see how well the medication works in everyday practice, not just in controlled trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trimbow (a triple combination inhaler containing beclometasone, formoterol, and glycopyrronium)
What this could lead to
If successful, this study could confirm that Trimbow helps control symptoms and reduce flare-ups in people with severe COPD in real-world settings.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also relatively small and short-term, so findings may not apply to all COPD patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Santa Casa de Misericórdia de São Paulo
RECRUITINGSão Paulo, São Paulo, 01221-020, Brazil
Contact Email: •••••@•••••